{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:05:29Z","timestamp":1792695929404,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG 3E142 and CMRPG 3F136"],"award-info":[{"award-number":["CMRPG 3E142 and CMRPG 3F136"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s12035-017-0845-3","type":"journal-article","created":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T02:31:33Z","timestamp":1514860293000},"page":"6319-6328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":147,"title":["Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"55","author":[{"given":"Kuo-Hsuan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Ling","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiang-Yu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Yu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yih-Ru","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0769-0353","authenticated-orcid":false,"given":"Chiung-Mei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"issue":"15","key":"845_CR1","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1056\/NEJM199810083391506","volume":"339","author":"AE Lang","year":"1998","unstructured":"Lang AE, Lozano AM (1998) Parkinson\u2019s disease. N Engl J Med 339(15):1044\u20131053. \nhttps:\/\/doi.org\/10.1056\/NEJM199810083391506","journal-title":"N Engl J Med"},{"issue":"3","key":"845_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pneurobio.2004.05.002","volume":"73","author":"OB Halbach","year":"2004","unstructured":"Halbach OB, Schober A, Krieglstein K (2004) Genes, proteins, and neurotoxins involved in Parkinson\u2019s disease. Prog Neurobiol 73(3):151\u2013177. \nhttps:\/\/doi.org\/10.1016\/j.pneurobio.2004.05.002","journal-title":"Prog Neurobiol"},{"key":"845_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.freeradbiomed.2013.01.018","volume":"62","author":"DT Dexter","year":"2013","unstructured":"Dexter DT, Jenner P (2013) Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med 62:132\u2013144. \nhttps:\/\/doi.org\/10.1016\/j.freeradbiomed.2013.01.018","journal-title":"Free Radic Biol Med"},{"issue":"1","key":"845_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1423-0127-16-63","volume":"16","author":"SS Ahmed","year":"2009","unstructured":"Ahmed SS, Santosh W, Kumar S, Christlet HTT (2009) Metabolic profiling of Parkinson\u2019s disease: evidence of biomarker from gene expression analysis and rapid neural network detection. J Biomed Sci 16(1):1\u201312. \nhttps:\/\/doi.org\/10.1186\/1423-0127-16-63","journal-title":"J Biomed Sci"},{"issue":"2","key":"845_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/brain\/awm304","volume":"131","author":"M Bogdanov","year":"2008","unstructured":"Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M (2008) Metabolomic profiling to develop blood biomarkers for Parkinson\u2019s disease. Brain 131(2):389\u2013396. \nhttps:\/\/doi.org\/10.1093\/brain\/awm304","journal-title":"Brain"},{"issue":"2","key":"845_CR6","doi-asserted-by":"publisher","first-page":"e0172348","DOI":"10.1371\/journal.pone.0172348","volume":"12","author":"RB Chan","year":"2017","unstructured":"Chan RB, Perotte AJ, Zhou B, Liong C, Shorr EJ, Marder KS, Kang UJ, Waters CH et al (2017) Elevated GM3 plasma concentration in idiopathic Parkinson\u2019s disease: a lipidomic analysis. PLoS One 12(2):e0172348. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0172348","journal-title":"PLoS One"},{"issue":"3","key":"845_CR7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2014-309676","volume":"87","author":"T Hatano","year":"2016","unstructured":"Hatano T, Saiki S, Okuzumi A, Mohney RP, Hattori N (2016) Identification of novel biomarkers for Parkinson\u2019s disease by metabolomic technologies. J Neurol Neurosurg Psychiatry 87(3):295\u2013301. \nhttps:\/\/doi.org\/10.1136\/jnnp-2014-309676","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"845_CR8","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/jnc.14104","volume":"142","author":"JF Havelund","year":"2017","unstructured":"Havelund JF, Andersen AD, Binzer M, Blaabjerg M, Heegaard NHH, Stenager E, Faergeman NJ, Gramsbergen JB (2017) Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. J Neurochem 142(5):756\u2013766. \nhttps:\/\/doi.org\/10.1111\/jnc.14104","journal-title":"J Neurochem"},{"issue":"10","key":"845_CR9","doi-asserted-by":"publisher","first-page":"e7551","DOI":"10.1371\/journal.pone.0007551","volume":"4","author":"KK Johansen","year":"2009","unstructured":"Johansen KK, Wang L, Aasly JO, White LR, Matson WR, Henchcliffe C, Beal MF, Bogdanov M (2009) Metabolomic profiling in LRRK2-related Parkinson\u2019s disease. PLoS One 4(10):e7551. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0007551","journal-title":"PLoS One"},{"issue":"10","key":"845_CR10","doi-asserted-by":"publisher","first-page":"e77629","DOI":"10.1371\/journal.pone.0077629","volume":"8","author":"JR Roede","year":"2013","unstructured":"Roede JR, Uppal K, Park Y, Lee K, Tran V, Walker D, Strobel FH, Rhodes SL et al (2013) Serum metabolomics of slow vs. rapid motor progression Parkinson\u2019s disease: a pilot study. PLoS One 8(10):e77629. \nhttps:\/\/doi.org\/10.1371\/journal.pone.0077629","journal-title":"PLoS One"},{"issue":"3","key":"845_CR11","doi-asserted-by":"publisher","first-page":"549","DOI":"10.3233\/JPD-140389","volume":"4","author":"M Trupp","year":"2014","unstructured":"Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, Wuolikainen A, Linder J et al (2014) Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson\u2019s disease. J Parkinsons Dis 4(3):549\u2013560. \nhttps:\/\/doi.org\/10.3233\/JPD-140389","journal-title":"J Parkinsons Dis"},{"issue":"3","key":"845_CR12","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","volume":"55","author":"AJ Hughes","year":"1992","unstructured":"Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181\u2013184. \nhttps:\/\/doi.org\/10.1136\/jnnp.55.3.181","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"845_CR13","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1212\/WNL.17.5.427","volume":"17","author":"MM Hoehn","year":"1967","unstructured":"Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17(5):427\u2013442. \nhttps:\/\/doi.org\/10.1212\/WNL.17.5.427","journal-title":"Neurology"},{"issue":"15","key":"845_CR14","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/mds.23429","volume":"25","author":"CL Tomlinson","year":"2010","unstructured":"Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE (2010) Systematic review of levodopa dose equivalency reporting in Parkinson\u2019s disease. Mov Disord 25(15):2649\u20132653. \nhttps:\/\/doi.org\/10.1002\/mds.23429","journal-title":"Mov Disord"},{"issue":"3","key":"845_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975) \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12(3):189\u2013198. \nhttps:\/\/doi.org\/10.1016\/0022-3956(75)90026-6","journal-title":"J Psychiatr Res"},{"issue":"11","key":"845_CR16","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43(11):2412\u20132414. \nhttps:\/\/doi.org\/10.1212\/WNL.43.11.2412-a","journal-title":"Neurology"},{"issue":"6","key":"845_CR17","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","volume":"72","author":"ME MacDonald","year":"1993","unstructured":"MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA et al (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72(6):971\u2013983. \nhttps:\/\/doi.org\/10.1016\/0092-8674(93)90585-E","journal-title":"Cell"},{"issue":"6","key":"845_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1002\/mds.26992","volume":"32","author":"F Burt\u00e9","year":"2017","unstructured":"Burt\u00e9 F, Houghton D, Lowes H, Pyle A, Nesbitt S, Yarnall A, Yu-Wai-Man P, Burn DJ et al (2017) Metabolic profiling of Parkinson\u2019s disease and mild cognitive impairment. Mov Disord 32(6):927\u2013932. \nhttps:\/\/doi.org\/10.1002\/mds.26992","journal-title":"Mov Disord"},{"key":"845_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jnutbio.2015.12.001","volume":"31","author":"ML Cheng","year":"2016","unstructured":"Cheng ML, Chang KH, Wu YR, Chen CM (2016) Metabolic disturbances in plasma as biomarkers for Huntington\u2019s disease. J Nutr Biochem 31:38\u201344. \nhttps:\/\/doi.org\/10.1016\/j.jnutbio.2015.12.001","journal-title":"J Nutr Biochem"},{"issue":"2","key":"845_CR20","doi-asserted-by":"publisher","first-page":"204","DOI":"10.2478\/v10039-010-0023-6","volume":"55","author":"E Gulaj","year":"2010","unstructured":"Gulaj E, Pawlak K, Bien B, Pawlak D (2010) Kynurenine and its metabolites in Alzheimer\u2019s disease patients. Adv Med Sci 55(2):204\u2013211. \nhttps:\/\/doi.org\/10.2478\/v10039-010-0023-6","journal-title":"Adv Med Sci"},{"issue":"8","key":"845_CR21","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/j.1742-4658.2012.08551.x","volume":"279","author":"AM Myint","year":"2012","unstructured":"Myint AM (2012) Kynurenines: from the perspective of major psychiatric disorders. FEBS J 279(8):1375\u20131385. \nhttps:\/\/doi.org\/10.1111\/j.1742-4658.2012.08551.x","journal-title":"FEBS J"},{"issue":"2","key":"845_CR22","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.bbr.2007.08.007","volume":"186","author":"L Gr\u00e9goire","year":"2008","unstructured":"Gr\u00e9goire L, Rassoulpour A, Guidetti P, Samadi P, B\u00e9dard PJ, Izzo E, Schwarcz R, Di Paolo T (2008) Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys. Behav Brain Res 186(2):161\u2013167. \nhttps:\/\/doi.org\/10.1016\/j.bbr.2007.08.007","journal-title":"Behav Brain Res"},{"issue":"3","key":"845_CR23","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.nbd.2004.07.006","volume":"17","author":"P Guidetti","year":"2004","unstructured":"Guidetti P, Luthi-Carter RE, Augood SJ, Schwarcz R (2004) Neostriatal and cortical quinolinate levels are increased in early grade Huntington\u2019s disease. Neurobiol Dis 17(3):455\u2013461. \nhttps:\/\/doi.org\/10.1016\/j.nbd.2004.07.006","journal-title":"Neurobiol Dis"},{"issue":"1","key":"845_CR24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0022-510X(94)00280-2","volume":"130","author":"D Jauch","year":"1995","unstructured":"Jauch D, Urba\u0144ska EM, Guidetti P, Bird ED, Vonsattel JPG, Whetsell WO Jr, Schwarcz R (1995) Dysfunction of brain kynurenic acid metabolism in Huntington\u2019s disease: focus on kynurenine aminotransferases. J Neurol Sci 130(1):39\u201347. \nhttps:\/\/doi.org\/10.1016\/0022-510X(94)00280-2","journal-title":"J Neurol Sci"},{"issue":"6","key":"845_CR25","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1034\/j.1600-0404.2003.00076.x","volume":"107","author":"J Ilzecka","year":"2003","unstructured":"Ilzecka J, Kocki T, Stelmasiak Z, Turski WA (2003) Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis. Acta Neurol Scand 107(6):412\u2013418. \nhttps:\/\/doi.org\/10.1034\/j.1600-0404.2003.00076.x","journal-title":"Acta Neurol Scand"},{"issue":"9","key":"845_CR26","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1212\/WNL.42.9.1702","volume":"42","author":"T Ogawa","year":"1992","unstructured":"Ogawa T, Matson WR, Beal MF, Myers RH, Bird ED, Milbury P, Saso S (1992) Kynurenine pathway abnormalities in Parkinson\u2019s disease. Neurology 42(9):1702\u20131706. \nhttps:\/\/doi.org\/10.1212\/WNL.42.9.1702","journal-title":"Neurology"},{"issue":"12","key":"845_CR27","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/mds.25555","volume":"28","author":"PA Lewitt","year":"2013","unstructured":"Lewitt PA, Li J, Lu M, Beach TG, Adler CH, Guo L, Arizona Parkinson's Disease C (2013) 3-Hydroxykynurenine and other Parkinson\u2019s disease biomarkers discovered by metabolomic analysis. Mov Disord 28(12):1653\u20131660. \nhttps:\/\/doi.org\/10.1002\/mds.25555","journal-title":"Mov Disord"},{"issue":"1","key":"845_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2005.07.006","volume":"239","author":"Z Hartai","year":"2005","unstructured":"Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L (2005) Kynurenine metabolism in plasma and in red blood cells in Parkinson\u2019s disease. J Neurol Sci 239(1):31\u201335. \nhttps:\/\/doi.org\/10.1016\/j.jns.2005.07.006","journal-title":"J Neurol Sci"},{"issue":"4","key":"845_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/s0014-2999(81)90587-2","volume":"72","author":"TW Stone","year":"1981","unstructured":"Stone TW, Perkins MN (1981) Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur J Pharmacol 72(4):411\u2013412. \nhttps:\/\/doi.org\/10.1016\/s0014-2999(81)90587-2","journal-title":"Eur J Pharmacol"},{"issue":"4582","key":"845_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1126\/science.6849138","volume":"219","author":"R Schwarcz","year":"1983","unstructured":"Schwarcz R, Whetsell WO Jr, Mangano RM (1983) Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219(4582):316\u2013318. \nhttps:\/\/doi.org\/10.1126\/science.6849138","journal-title":"Science"},{"issue":"2","key":"845_CR31","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0197-0186(97)90002-4","volume":"30","author":"S S\u02c7t\u00edpek","year":"1997","unstructured":"S\u02c7t\u00edpek S, S\u02c7tastn\u00fd FE, Pl\u00e1ten\u00edk J, Crkovsk\u00e1 JI, Zima T (1997) The effect of quinolinate on rat brain lipid peroxidation is dependent on iron. Neurochem Int 30(2):233\u2013237. \nhttps:\/\/doi.org\/10.1016\/S0197-0186(97)90002-4","journal-title":"Neurochem Int"},{"issue":"5","key":"845_CR32","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/10715760100300391","volume":"34","author":"J Pl\u00e1ten\u00edk","year":"2001","unstructured":"Pl\u00e1ten\u00edk J, Stopka P, Vejra\u017eka M, \u0160t\u00edpek S (2001) Quinolinic acid\u2014iron(II) complexes: slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction. Free Radic Res 34(5):445\u2013459. \nhttps:\/\/doi.org\/10.1080\/10715760100300391","journal-title":"Free Radic Res"},{"issue":"1","key":"845_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12640-009-9051-z","volume":"16","author":"N Braidy","year":"2009","unstructured":"Braidy N, Grant R, Adams S, Brew BJ, Guillemin GJ (2009) Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox Res 16(1):77\u201386. \nhttps:\/\/doi.org\/10.1007\/s12640-009-9051-z","journal-title":"Neurotox Res"},{"key":"845_CR34","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.semcdb.2015.03.002","volume":"40","author":"DC Maddison","year":"2015","unstructured":"Maddison DC, Giorgini F (2015) The kynurenine pathway and neurodegenerative disease. Semin Cell Dev Biol 40:134\u2013141. \nhttps:\/\/doi.org\/10.1016\/j.semcdb.2015.03.002","journal-title":"Semin Cell Dev Biol"},{"issue":"5","key":"845_CR35","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.ntt.2011.07.002","volume":"33","author":"R Lugo-Huitr\u00f3n","year":"2011","unstructured":"Lugo-Huitr\u00f3n R, Blanco-Ayala T, Ugalde-Mu\u00f1iz P, Carrillo-Mora P, Pedraza-Chaverr\u00ed J, Silva-Adaya D, Maldonado PD, Torres I et al (2011) On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol Teratol 33(5):538\u2013547. \nhttps:\/\/doi.org\/10.1016\/j.ntt.2011.07.002","journal-title":"Neurotoxicol Teratol"},{"issue":"19","key":"845_CR36","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","volume":"21","author":"C Hilmas","year":"2001","unstructured":"Hilmas C, Pereira EFR, Alkondon M, Rassoulpour A, Schwarcz R, Albuquerque EX (2001) The brain metabolite kynurenic acid inhibits \u03b17 nicotinic receptor activity and increases non-\u03b17 nicotinic receptor expression: physiopathological implications. J Neurosci 21(19):7463\u20137473","journal-title":"J Neurosci"},{"issue":"1","key":"845_CR37","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/0006-8993(82)91048-4","volume":"247","author":"MN Perkins","year":"1982","unstructured":"Perkins MN, Stone TW (1982) An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 247(1):184\u2013187. \nhttps:\/\/doi.org\/10.1016\/0006-8993(82)91048-4","journal-title":"Brain Res"},{"issue":"1","key":"845_CR38","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1196\/annals.1320.003","volume":"1033","author":"CJ Rebouche","year":"2004","unstructured":"Rebouche CJ (2004) Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci 1033(1):30\u201341. \nhttps:\/\/doi.org\/10.1196\/annals.1320.003","journal-title":"Ann N Y Acad Sci"},{"issue":"4","key":"845_CR39","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1073\/pnas.261708898","volume":"99","author":"TM Hagen","year":"2002","unstructured":"Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, Bartholomew JC, Ames BN (2002) Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci U S A 99(4):1870\u20131875. \nhttps:\/\/doi.org\/10.1073\/pnas.261708898","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"845_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/0165-6147(93)90093-Y","volume":"14","author":"IB Fritz","year":"1993","unstructured":"Fritz IB, Arrigoni-Martelli E (1993) Sites of action of carnitine and its derivatives on the cardiovascular system: interactions with membranes. Trends Pharmacol Sci 14(10):355\u2013360. \nhttps:\/\/doi.org\/10.1016\/0165-6147(93)90093-Y","journal-title":"Trends Pharmacol Sci"},{"key":"845_CR41","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.nbd.2012.10.011","volume":"51","author":"DN Hauser","year":"2013","unstructured":"Hauser DN, Hastings TG (2013) Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease and monogenic parkinsonism. Neurobiol Dis 51:35\u201342. \nhttps:\/\/doi.org\/10.1016\/j.nbd.2012.10.011","journal-title":"Neurobiol Dis"},{"issue":"11","key":"845_CR42","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1007\/s11064-011-0542-y","volume":"36","author":"XQ Tang","year":"2011","unstructured":"Tang XQ, Fang HR, Li YJ, Zhou CF, Ren YK, Chen RQ, Wang CY, Hu B (2011) Endogenous hydrogen sulfide is involved in asymmetric dimethylarginine-induced protection against neurotoxicity of 1-methyl-4-phenyl-pyridinium ion. Neurochem Res 36(11):2176\u20132185. \nhttps:\/\/doi.org\/10.1007\/s11064-011-0542-y","journal-title":"Neurochem Res"},{"issue":"3","key":"845_CR43","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/BF03159973","volume":"16","author":"W Paschen","year":"1992","unstructured":"Paschen W (1992) Polyamine metabolism in different pathological states of the brain. Mol Chem Neuropathol 16(3):241\u2013271. \nhttps:\/\/doi.org\/10.1007\/BF03159973","journal-title":"Mol Chem Neuropathol"},{"issue":"1","key":"845_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1046\/j.1471-4159.1998.71010288.x","volume":"71","author":"LD Morrison","year":"1998","unstructured":"Morrison LD, Cao XC, Kish SJ (1998) Ornithine decarboxylase in human brain: influence of aging, regional distribution, and Alzheimer\u2019s disease. J Neurochem 71(1):288\u2013294. \nhttps:\/\/doi.org\/10.1046\/j.1471-4159.1998.71010288.x","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"845_CR45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0006-8993(98)00577-0","volume":"802","author":"A Rassoulpour","year":"1998","unstructured":"Rassoulpour A, Wu H-Q, Poeggeler B, Schwarcz R (1998) Systemic d-amphetamine administration causes a reduction of kynurenic acid levels in rat brain. Brain Res 802(1\u20132):111\u2013118. \nhttps:\/\/doi.org\/10.1016\/S0006-8993(98)00577-0","journal-title":"Brain Res"},{"issue":"3","key":"845_CR46","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s007020200020","volume":"109","author":"HQ Wu","year":"2002","unstructured":"Wu HQ, Rassoulpour A, Schwarcz R (2002) Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum. J Neural Transm 109(3):239\u2013249. \nhttps:\/\/doi.org\/10.1007\/s007020200020","journal-title":"J Neural Transm"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-017-0845-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-017-0845-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-017-0845-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T22:33:52Z","timestamp":1532039632000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-017-0845-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,2]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1007\/s12035-017-0845-3","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,2]]}}}